Business Trip FDA advisors say no to MDMA. What’s the impact? With Josh Hardman
Jun 21, 2024
In this engaging discussion, Josh Hardman, founder and editor of Psychedelic Alpha, tackles the FDA's recent rejection of MDMA for PTSD therapy. He explores the complexities of the FDA advisory process and highlights the challenges in data gaps and potential biases in clinical trials. Hardman delves into the future of psychedelic treatments and the rising importance of non-hallucinogenic therapies. The conversation also touches on the implications for insurance coverage and regulatory pathways, painting a vivid picture of the evolving landscape in mental health treatment.
Chapters
Transcript
Episode notes
1 2 3 4 5 6 7
Intro
00:00 • 3min
Navigating MDMA's Approval Challenges
02:37 • 25min
Challenges in Treatment Rollout: A Controlled Approach and Reimbursement Concerns
28:01 • 2min
Navigating Psychedelic Therapy's Future
30:20 • 17min
Navigating Drug Approval and Cost-Effective Healthcare Innovations
47:04 • 2min
Exploring the Intersection of Psychedelics and Psychotherapy in Clinical Trials
49:19 • 6min
Navigating Difficult Topics in Mental Health Journalism
54:58 • 2min